These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22385796)

  • 1. TGFβ1 SNPs and radio-induced toxicity in prostate cancer patients.
    Fachal L; Gómez-Caamaño A; Sánchez-García M; Carballo A; Peleteiro P; Lobato-Busto R; Carracedo A; Vega A
    Radiother Oncol; 2012 May; 103(2):206-9. PubMed ID: 22385796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients.
    Fachal L; Gómez-Caamaño A; Peleteiro P; Carballo A; Calvo-Crespo P; Sánchez-García M; Lobato-Busto R; Carracedo A; Vega A
    Radiother Oncol; 2012 Dec; 105(3):321-8. PubMed ID: 23075580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFβ1 gene.
    De Langhe S; De Ruyck K; Ost P; Fonteyne V; Werbrouck J; De Meerleer G; De Neve W; Thierens H
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):393-9. PubMed ID: 22658438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity outcome after three-dimensional conformal radiotherapy for early stage prostatic cancer.
    Kurtman C
    Radiat Med; 2001; 19(2):89-92. PubMed ID: 11383648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-dimensional conformal external beam radiotherapy.
    Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Serafini F; Cambria R; Vavassori A; Cattani F; Garibaldi C; Gherardi F; Ferrari A; Rocco B; Scardino E; de Cobelli O; Orecchia R
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):26-34. PubMed ID: 20133085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy.
    Nichol A; Chung P; Lockwood G; Rosewall T; Divanbiegi L; Sweet J; Toi A; Bayley A; Bristow R; Crook J; Gospodarowicz M; McLean M; Milosevic M; Warde P; Catton C
    Radiother Oncol; 2005 Jul; 76(1):11-7. PubMed ID: 15990187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy.
    Peters CA; Stock RG; Cesaretti JA; Atencio DP; Peters S; Burri RJ; Stone NN; Ostrer H; Rosenstein BS
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):752-9. PubMed ID: 17689884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer.
    Suga T; Iwakawa M; Tsuji H; Ishikawa H; Oda E; Noda S; Otsuka Y; Ishikawa A; Ishikawa K; Shimazaki J; Mizoe JE; Tsujii H; Imai T
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):808-13. PubMed ID: 18374504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients.
    Langsenlehner T; Renner W; Gerger A; Hofmann G; Thurner EM; Kapp KS; Langsenlehner U
    Radiother Oncol; 2011 Mar; 98(3):387-93. PubMed ID: 21345510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study.
    Vavassori V; Fiorino C; Rancati T; Magli A; Fellin G; Baccolini M; Bianchi C; Cagna E; Mauro FA; Monti AF; Munoz F; Stasi M; Franzone P; Valdagni R
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1401-10. PubMed ID: 17241754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.
    Karlsdóttir A; Johannessen DC; Muren LP; Wentzel-Larsen T; Dahl O
    Radiother Oncol; 2004 Apr; 71(1):43-53. PubMed ID: 15066295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of association of transforming growth factor-beta1 polymorphisms and haplotypes with prostate cancer risk in the prostate, lung, colorectal, and ovarian trial.
    Kang D; Lee KM; Park SK; Berndt SI; Reding D; Chatterjee N; Welch R; Chanock S; Huang WY; Hayes RB
    Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1303-5. PubMed ID: 17548703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.